Abstract Neonatal hypoxia-ischemia (HI) is a devastating condition resulting in neuronal cell death and often culmi-
Introduction
Hypoxic-ischemic (HI) brain injury remains a leading cause of mortality and morbidity in infants and affects 2-4 of 1000 full-term births and nearly 60 % of premature births [1, 2] . Among survivors, 20-40 % develop significant neurological impairments such as cerebral palsy, mental retardation, and epilepsy associated with life-long medical, social, emotional, and economic difficulties [3, 4] . However, effective treatment avenues are still lacking; thus necessitating alternative strategies to either replace or amplify current therapeutic protocols.
Granulocyte-colony stimulating factor (G-CSF) and stem cell factor (SCF) are hematopoietic growth factors which play a role in hematopoiesis [5] . G-CSF is produced by a number of different cells (endothelium, macrophages, and some immune cells) to stimulate the bone marrow to release stem cells and granulocytes. Its receptor is present on precursor cells in the bone marrow which when activated initiates proliferation and differentiation into mature granulocytes. Recently, it has also been shown that it also has receptors expressed on neurons in the brain and spinal cord which, when activated by G-CSF, induces neurogenesis, increases neuroplasticity, and reduces apoptosis [6, 7] . G-CSF stimulates survival, proliferation and development of neuronal stem cells and was in Phase I/II clinical trials for ischemic stroke treatment [6, 8, 9] . Multiple studies have shown that G-CSF is capable of conferring neuroprotection in a variety of in vivo brain injury models [10] [11] [12] [13] . It was reported that rats treated with G-CSF after middle cerebral artery occlusion (MCAO) have smaller infarcts and better functional outcome compared with controls [14] . Furthermore, it has also been shown that G-CSF prevented brain tissue loss and improved long-term neurological outcome in the neonatal HI model [15] . SCF binds to the tyrosine kinase receptor (c-kit) which is expressed on both primitive and mature hematopoietic progenitor cells. Once bound to its receptor it mediates cell proliferation, differentiation and migration in hematopoiesis [16] . In vivo, SCF acts synergistically with G-CSF to mobilize and promote proliferation and survival of pluripotent progenitor cells [17, 18] , and promote neuronal production from bone marrow [19] .
Recently, accumulating evidence has shown that both G-CSF and SCF have therapeutic effects on the central nervous system [5] . SCF mutant mice showed deficits in special learning and memory [20] while G-CSF has been shown to have neuroprotective effect on brain ischemia. The administration of G-CSF alone [21] [22] [23] or in combination with SCF [23] during the acute phase of brain ischemia, or the subcutaneous injection of G-CSF+SCF during the subacute phase of brain ischemia [9] resulted in an reduction of infarction size. However, no study to date has examined whether administration of G-CSF with SCF induced neuroprotection translates into improvements in neurological outcome at the chronic phase of brain ischemia and whether there is an additive benefit against brain and peripheral organ atrophy with the coadministration treatment in neonatal HI.
We hypothesized that G-CSF in combination with SCF will not only have neuroprotective activity by reducing brain atrophy but will also show significant improvement in the neurological outcome after HI in neonatal rats. G-CSF, SCF and G-CSF+SCF were administered 1 h post HI followed by daily injection for four consecutive days, and brain atrophy, organ weights, and neurological outcome was measured at 14 days post HI.
Materials and Methods
All procedures and protocols were approved by the Institutional Animal Care and Use Committee of Loma University.
All animal handling was executed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Sprague Dawley rat mothers, with litters of 10-12 pups, were purchased from Harlan Labs (Livermore, CA). A total of 44 unsexed rat pups were used. They were divided into the following groups: sham (n08), HI+Vehicle (n08), HI+ G-CSF (n09), HI+SCF (n09) and HI+G-CSF+SCF (n010).
Hypoxia-Ischemia Model/Operative Procedure
The standard Rice-Vannucci neonatal Hypoxia-Ischemia model was used as previously described [24] . Briefly, 7 days after birth (P7), neonatal rat pups were placed into a temperature-controlled chamber for the induction of general anesthesia which was achieved with 3 % isoflurane gas in air for induction, and 1.5 % isoflurane in air for maintenance of anesthesia. Throughout the surgical and postoperative period, temperature was controlled with heating blankets and incubators. After induction of anesthesia the neck of the rats was prepared and draped using standard sterile techniques. Next, a small midline neck incision on the anterior neck was made with a No. 11 blade surgical knife (approximately 3-5 mm in length). Using gentle blunt dissection, the right common carotid artery was isolated and gently separated from surrounding structures. The carotid artery was then ligated with 5-O surgical suture. Bleeding was controlled with gentle pressure and electrocautery as needed. The surgery was performed aseptically and its duration did not exceed more than 15 min. After the surgical procedure was completed, the rats were allowed to recover for 1 h. Thereafter, they were placed in a 500-ml airtight jar partially submerged in a 37°C water bath to maintain a constant thermal environment. A gas mixture of 8 % oxygen and 92 % nitrogen was delivered into the jars through inlet portals. The rat pups were exposed to this gas mixture for 2 h and 30 min. Thereafter, animals were returned to their mothers.
Treatment Method
Rat pups were allowed to rest for 1 h on a warm blanket before initiating therapy. Mouse recombinant SCF (50 μg/kg) (PeproTech, Rocky, USA), human recombinant G-CSF (50 μg/kg) (Amgen, Thousand Oaks, USA), G-CSF and SCF together or PBS were administered intraperitoneally daily for 4 days after the first injection at 1 h after HI (a total of 5 injections). The doses for G-CSF and SCF chosen were previously shown to be affective in other ischemia models [15, 25] .
Evaluation of Brain Damage and Systemic Organ Weight
The HI animal model shows brain damage on the ipsilateral side [26, 27] , commonly assessed by hemispheric brain weight loss, which is highly correlated to histological loss of brain tissue [28, 29] . Brain tissue (sham: n08; vehicle: n08; G-CSF: n09; SCF: n09; G-CSF+SCF: n010) was removed, and the hemispheres were separated by a midline incision and weighed on a high-precision balance (sensitivity±0.001 g). Data are expressed as the ratio of ipsilateral (right) to contralateral (left) hemispheric weights. The heart, spleen, liver, and kidney were also isolated and weighed. Data for systemic organs are expressed as the ratio of organ weight to body weight.
Neurobehavioral Tests
Modified Garcia and foot fault test were performed in order to assess the long-term sensorimotor dysfunction in rats 14 days post HI as previously described [30, 31] . Briefly, the modified Garcia test is a 21-point sensorimotor assessment system consisting of seven tests with scores of 0 to 3 for each individual test (with 0 being worst score and 3 best; maximum score021). These seven tests evaluated spontaneous activity (1), reaction following side stroking (2) and vibrissae touch (3), limb symmetry (4), climbing (5), lateral turning (6), and forelimb walking (7) .
The foot fault test is a test of motor coordination. The apparatus consists of a grid floor. The grid is suspended or raised above a surface. Each animal is placed at one end of the grid and monitored for 2 min from the side as they walk across the grid. The number of forelimb and hind limb placement errors as the animal traverses the grid is scored. An error is counted whenever a limb misses a bar and extends downward through the plane of the bars.
Statistical Analysis
All data were expressed as mean±SEM. Statistical differences between groups were analyzed with one-way ANOVA followed by Tukey multiple-comparison post hoc analysis or Student-Newman-Keuls test on ranks. A p value of <0.05 was considered statistically significant.
Results
Treatment with G-CSF and SCF Improved Physical Development after HI Figure 1a shows the difference in physical development between rats injected with vehicle (PBS), G-CSF, SCF or G-CSF+SCF at the completion of the 5-day treatment period. At 14 days post HI, vehicle rats (n08) had gained significantly less weight compared to sham (n08), numbers in parenthesis represent mean raw score±standard error (p<0.05, 33.919± 0.693 vs 44.413±1.454 g) which was attenuated by G-CSF, SCF (n09) and G-CSF+SCF (n010) Combinational Treatment of G-CSF with SCF Reduced Brain Atrophy and Tends to Improve Peripheral Organ Weight HI injury caused severe brain atrophy of the lesioned hemisphere as seen in Fig. 1b (arrows represent the injured side) . Rats injected with G-CSF resulted in significantly lesser brain tissue atrophy when analyzed at 14 days post HI compared to vehicle (p<0.05, 0.825±0.0515 vs 0.621± 0.0575 right-to-left brain weight ratio). A tendency was seen in rats injected with SCF only, to reduce brain tissue atrophy in comparison to vehicle, nevertheless no statistical significant difference was found between the groups. However, rats injected with both G-CSF and SCF showed significant less brain tissue atrophy when compared to vehicle and SCF only treatment group (p<0.05; 0.902±0.0357 vs 0.621± 0.0575 vs 0.708±0.0547 right to left brain weight ratio). Although G-CSF, SCF and G-CSF+SCF treatment had a tendency to improve spleen, liver, kidney and heart weights, no statistical significant difference was detected between the groups. As seen from Fig. 2 , vehicle rats tend to have smaller liver compared to sham and G-CSF treatment showed to be most effective in increasing liver size, but once again there is no significant difference between the groups.
G-CSF and SCF Improved Neurological Outcome at 2 Weeks Post HI In order to test the effects of G-CSF, SCF and G-CSF+SCF treatment on the neurobehavioral impairments induced by HI, neurological outcome was assessed using modified Garcia test and foot fault test at 14 days after HI. In both behavioural tests, animals in the vehicle group performed significantly worse than sham operated rats (p<0.05). In the modified Garcia test, rats administered with G-CSF or SCF showed a tendency to improve neurological outcome however no significance was reached. Nonetheless, the combinational treatment of G-CSF+SCF showed to significantly improve neurological outcome compared to vehicle treated rats (p<0.05, 19.7±0.213 vs 14.875±0.479). In addition, the combinational treatment group also significantly improved the sensorimotor coordination as assessed by foot fault test (p<0.05, compared to vehicle; 0.186±0.0106 vs 0.378±0.0117). The animals in the G-CSF or SCF groups did not show any significant improvements (Fig. 3) 
Discussion
This study demonstrates the efficacy of G-CSF+SCF combination therapy for prevention of brain atrophy and improvement of neurological function in established rat model of neonatal HI injury. Our data show that G-CSF+SCF improved body weight, reduce brain tissue loss and improved the neurological outcome following HI in the neonatal rat pups. These findings provide important information for potential development of new therapeutic strategies against HI-induced brain injury in neonates.
Hypoxia-ischemia is a devastating condition that causes severe brain damage to the newborn infant. To date, effective treatment avenues are still lacking hence the need for future research in this field. The current study focuses on two major bone marrow related growth factors, G-CSF and SCF which might have a promising therapeutic effect in the onset of stroke. Both G-CSF and SCF are known to stimulate the survival, proliferation and differentiation of bone marrow cells, such as the hematopoietic cells [32] [33] [34] [35] [36] [37] . While G-CSF is important for stimulating the production and recruitment of cells from the bone marrow into the circulation, SCF might be responsible for the proliferation of vascular endothelial cells, many of which are derived from the bone marrow [25] . Furthermore, coadministration of G-CSF with SCF may further increase G-CSF protective effect by increasing tyrosine kinase-related downstream effects and increasing prosurvival signals [38] . Phase I/II clinical trials have shown that SCF treatment alone resulted in little effect on peripheral blood or bone marrow cell numbers. However, when combined with G-CSF it showed a two-to threefold increase in cells that express CD34 antigen (cells expressing this antigen are hematopoietic cells, progenitor cells, endothelial cells, etc., critical for prosurvival) [18, 39] . Previous studies also reported that when G-CSF was combined with SCF, it further increased CD34+ circulating cells versus treatment with G-CSF alone [32] , hence, further enhancing G-CSF protective effect by increasing prosurvival signals [38] .
G-CSF is one of the most studied growth factors in the setting of stroke. Previous studies have reported that G-CSF can pass the blood brain barrier [40] and has shown to be neuroprotective in a rat model of focal cerebral ischemia [21, 41, 42] . Clinically, increasing evidences have shown the therapeutic potential of G-CSF and SCF in patients with ischemic stroke [8, 18, 43] . SCF has been found to stimulate early pluripotent and committed stem cells to form colonyforming units and act synergistically with other growth factors such as G-CSF to increase the production of hematopoietic cells [44, 45] . Previous findings have also reported G-CSF's ability to reduce lesion volumes and improve neurological outcome at 48 h after cerebral ischemia in rodents [21, 46] . Based on the above findings, it is of particular interest to us to study the effects of the combinational treatment of G-CSF with SCF on neurological outcome, brain atrophy, and peripheral organ protection. We tested this hypothesis by administering G-CSF, SCF, and a combination of G-CSF+ SCF at 1 h post HI and consecutively for 4 days. To our knowledge, the long-term neuroprotective effect of the combinational treatment has not been studied to date.
One of the main signs of HI-related outcome is growth retardation which can be used as an indicator for general well being [47] . Previous studies have shown that neonatal hypoxia-ischemia retards the development of somatic growth starting from 1 day after the insult [48, 49] . The body weight data in the present study showed that injured animals significantly lost weight at 14 days post HI while G-CSF or SCF treatment groups significantly reversed that effect. A similar result was seen in previous publication from our lab where G-CSF administered for 5 or 10 days significantly increased body weights when compared to vehicle treated animals [15] . However, the combinational treatment group even further improved weight gain (Fig. 1a) . This suggests that G-CSF+SCF treatment significantly improved physical development during the critical period following brain injury.
Aside from promoting weight gain, it is well known that HI causes brain injury which leads to high risks of future behavioural deficits [48] . Hence, we tested the effect of G-CSF+ SCF on injured rats and results showed that the treatment significantly reduced brain atrophy (Fig. 1b) . Animals in the combinational treatment group showed to prevent the loss of brain tissue. The anti-apoptotic and anti-inflammatory properties of those two growth factors might be responsible for attenuating long-term brain damage; however, the exact mechanism is still unknown. HI has been shown to affect not only the brain but other main peripheral organs. The interruption of blood flow to the brain causes a redistribution in cardiac output resulting in more blood pumped to the brain at the expense of blood flow to kidney, liver, spleen, etc. resulting in organ injury [50] . Body weight is accompanied by decreased weight in peripheral organs such as the heat, liver, spleen, and kidney [51, 52] . As stated above, one possible explanation would be the lack of adequate oxygen supply and lack of nutrients which result from preferential blood flow to the brain. Due to those effects seen in this study, we further went to measure the organ to body weight ratio (Fig. 2) , however, no statistical significant results were found between the groups. This might be because the neonatal rat can compensate for those losses. Although there was no Fig. 2 Treatment groups showed no effect on organ weight at 14 days post HI. Treatment did not appear to improve heart to body (a), liver to body (b), spleen to body (c) or kidney to body (d) weight ratios when measured 14 days post HI. Although G-CSF+SCF treatment appeared to show some improvement in the above listed organs, statistical significance was not reached statistically significant difference found, the combinational treatment group appeared to show some improvement in organ weights however the G-CSF only treated groups tend to have larger organs when compared to sham. This latter finding may be due to organ hypertrophy due to treatment with growth factor. Spleen enlargements in particular have been reported previously in naive and injured animals due to G-CSF and SCF administration [18, 53] . These findings are in agreement with previous studies form our lab, where it has been shown that G-CSF did not show any significant difference on peripheral organ weights [15] .
The hippocampus and the sensorimotor cortex are critical for regulation of sensorimotor function and are highly affected by HI [54] . As already known, damage to those regions causes severe deterioration in functional performance. According to modified Garcia and foot fault test G-CSF and SCF treatment groups alone did not show any significant improvement in neurological score, however the combinational treatment group did show significant improvements. According to the Garcia test, HI-injured rats performed poorly, which was reversed by the combinational treatment group. Similar effect was seen in foot fault where the percentage of foot faults to contralateral forelimb was high in HI-injured rats and reversed in treated animals. Our results are consistent with previous work done from our lab, where G-CSF given for 5 or 10 days promoted physical development, reduced brain atrophy and improved neurological outcome according to T-maze, foot fault, Garcia and rota rod tests at 5 weeks post HI [15] . From the present study and previous studies we can conclude that G-CSF shows significant neurological improvement as early as 2 weeks and as late as 5 weeks, and G-CSF+SCF showed even further improvement when assessed at 2 weeks post HI. A few more studies have been done in our lab on different models that have shown G-CSF to have similar neuroprotective outcome [55, 56] .
From this study we can conclude that G-CSF+SCF can improve body weight, reduce brain tissue atrophy and improve neurological outcome following HI in the neonatal rat pup. The exact mechanism through which G-CSF+SCF act to achieve this neuroprotective effect are not well understood. It is speculated that HI may activate intrinsic protective mechanisms to combat neonatal brain injury, which is consistent with prior observations [11] . G-CSF may decrease proapoptotic factors meanwhile increase antiapoptotic factors by activation of the JAK/STAT3 [57] , PI3K/Akt [6] and MAPK/ERK pathways which have been largely confirmed in brain ischemia models in vivo [22] . Combining G-CSF with SCF may further increase the protective effects of G-CSF by augmenting tyrosine kinaserelated effects and further increase prosurvival signals [38] .
Overall, the above findings from this study are clinically relevant and provide foundation for exploring clinical translation. Both G-CSF and SCF are attractive candidates for therapeutic treatment. They both showed neuroprotective properties, specifically attenuating long-term brain atrophy, and also have minimal side effects such as bone or musculoskeletal pain, anemia, thrombocytopenia, and injection site reactions [58, 59] . Nevertheless, the study anticipates the need for potentially a longer neurobehavioral assessment time period as well as a more comprehensive evaluation of safety before moving this treatment into clinical setting. 
